Zogenix (ZGNX) Misses Q4 EPS by 20c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Zogenix (ZGNX) Prices 8.52M Share Common Offering at $23/Sh
March 4, 2020 5:56 AM ESTZogenix, Inc. (NASDAQ: ZGNX) announced today that it has priced an underwritten public offering of 8,520,000 shares of its common stock at a price to the public of $23.50 per share. The gross proceeds to Zogenix from the offering, before underwriting discounts and commissions and offering... More
Zogenix, Inc. (ZGNX) PT Lowered to $25 at Ladenburg Thalmann
February 28, 2020 7:08 AM ESTLadenburg Thalmann analyst Michael Higgins lowered the price target on Zogenix, Inc. (NASDAQ: ZGNX) to $25.00 (from $35.00) while maintaining a Neutral rating.... More
Zogenix (ZGNX) Announces FDA Extension of Review Period for FINTEPLA in Dravet Syndrome
February 27, 2020 8:06 AM ESTZogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for FINTEPLA® for the treatment of seizures associated with Dravet syndrome. The new Prescription Drug User Fee Act (PDUFA) target... More
